Tender detail

Conclusion of a non-exclusive discount agreement for the active substance Ublituximab

Summary

DAK-Gesundheit intends to conclude non-exclusive discount agreements with pharmaceutical companies for medicines containing the active substance Ublituximab (ATC L04AG14). The agreements will run from 1 December 2026 to 30 November 2028, or end earlier if an exclusive agreement takes effect.

Reference number
1e08dd1f-4f97-45e0-8aef-44668fc811a4
Buyer
Country
Germany (DEU)
Procedure
Open procedure
CPV
33600000 Pharmaceutical products
Deadline
2028-10-05
Status
Open
Contract subject
Supplies
Estimated value
1,00 EUR
Source
DEU_BKMS

More tender information after sign-in

The public view shows key tender details. Sign in to open official links, documents and AI tender support.